A Case Report on Rituximab-induced Interstitial Lung Disease

¹Pharm D (PB), Department of Clinical Pharmacy, HCG Cancer Center, Vadodara, Gujarat, India

²Pharm D Intern, Parul Institute of Pharmacy and Research, Vadodara, Gujarat, India

³MBBS, MD, DM (Medical Oncology), Consultant Oncology, HCG Cancer Centre, Vadodara, Gujarat, India

*Corresponding Author: Dr. Nisarg Hajariwala, Clinical Pharmacist, HCG Cancer Centre, Vadodara, Vadodara, Gujarat, India; Tel: +91 79904 50749; Email: [email protected]

Received Date: March 2, 2023

Publication Date: April 15, 2023

Citation: Hajariwala N, et al. (2023). A Case Report on Rituximab-induced Interstitial Lung Disease. Mathews J Cancer Sci. 8(2):40.

Copyright: Hajariwala N, et al. © (2023)

ABSTRACT

Rituximab is a monoclonal antibody commonly used to treat various autoimmune diseases. However, its use has been associated with the development of interstitial lung disease (ILD), a severe and potentially fatal condition characterized by inflammation and fibrosis of the lungs. This case report describes the case of a patient who developed ILD following treatment with rituximab for Diffuse large B cell lymphoma. The patient presented with symptoms of shortness of breath, dry cough, and fever, and was diagnosed with ILD following a comprehensive evaluation. The patient was treated with corticosteroids and other immunosuppressive medications, with a favorable response. This report highlights the importance of recognizing and managing rituximab-induced ILD and underscores the need for close monitoring of patients receiving this drug.

Keywords: Interstitial lung disease, Diffuse large B cell lymphoma, Rituximab